May 2016 |
Multiple Myeloma
Study: Combination of ASCT and Bortezomib
|
|
Colorectal Cancer
Cancers Originating on Left Side of Colon
|
|
Drugs and Targets
FDA Approves Tecentriq, Opdivo, Imbruvica and Lenvima FDA granted accelerated approval to Tecentriq (atezolizumab) for urothelial carcinoma, the most common type of bladder cancer. This is the first product in its class of PD-1/PD-L1 inhibitors approved to treat this type of cancer, according to the drug’s sponsor, Genentech. Tecentriq is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgical treatment. Also: |
|
Non-Small Cell Lung Cancer | |
Melanoma
Phase Ib Trial Shows 40 Percent of Patients
|
|
|
Mesothelioma
WT1 Vaccine Doubles PFS in Phase II Trial |
|
Breast Cancer
LEE011 Meets Primary Endpoint, Improves PFS
|
|
Precision Medicine
Study: Precision Medicine Yields Better
|
|
Palliative Care
Study: Early Palliative Care Provides Benefits
|
|
NCI CTEP-Approved Trials for the Month of May |